Replies to post #289643 on NorthWest Biotherapeutics Inc (NWBO)

[marzan]

Ex, you are a very smart person. What do you mean by PFS story? You know this good OS can't be true unless PFS is contributing to it part or all of it. And LL says 50% of the trial population who are mesenchymal and most of them are progression free. Who else if said you will believe? She is the PI and I think she is meaning the Adjudicated ones because in all her life we know she said pseudoprogression is muddying havoc. And you acknowledge pseudoprogression exists here and you are not AVII who doesn't believe in that I think. Anyway, it is upto you to ride with us now or later after you see your confirmation in your own way but it could be pricey then.

[hope4patients]

PFS is a surrogate endpoint to determine future OS for trials that are “relatively” short....but you already knew that. We now have REAL OS data, not some future prediction based on PFS. OS is all that matters to patients...along with quality of life. DCVAX provides BOTH :)

[Lykiri]

I would not make any attempt to place odds. I am not investing now as overall I think LP and PFS make it a bad bet today. Once the PFS story resolves I could reconsider.

Ex,

I think the next comment from “Houston Methodist Leading Medicine” is hopeful:

In contrast, DCVax has achieved clinical benefits (i.e.longer delay in disease progression and longer extension of survival than with standard of care treatment) in over 80% of the patients who have received DCVax in clinical trials to date. Since DCVax is made with biomarkers from the patient’s own tumor, it is automatically tailored to targets that are present on that patient’s cancer.

https://www.houstonmethodist.org/1285_houstonmethodist/738_servicesandspecialties/2044_servicesandspecialities_neurologyandneurosurgery/2181_servicesandspecialities_locations/2183_servicesandspecialities_neurologicalinstitutetexasmedicalcenterhouston/2185_servicesandspecialities_clinicalprograms/609_forhealthcareprofessionals_kennethrpeakbrainandpituitarytreatmentcenter/newpage_peakcenter_clinicaltrial_intro/newpage_peakcenter_clinical-trials_dc-vax/
I believe that the Methodist Hospital in Houston was one of the 86 study locations.